As of now, there is a proposed class action lawsuit related to injuries caused by lecanemab infusions, but it is not yet clear if there is an officially open or widely consolidated class action. Two residents of New York have filed a proposed class action lawsuit concerning lecanemab, indicating that legal action is underway or being initiated regarding adverse effects from this drug. However, details about the scope, status, or whether it has been certified as a class action remain limited.
Lecanemab is a relatively new treatment approved for early-stage Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s. It works by targeting and clearing amyloid beta plaques in the brain, which are believed to contribute to cognitive decline. The drug was initially administered via intravenous infusions lasting about an hour, but recently, a subcutaneous autoinjector formulation was approved, allowing for quicker, at-home injections lasting about 15 seconds. This advancement aims to improve accessibility and reduce the burden of treatment for patients.
Despite its benefits in slowing cognitive decline, lecanemab has been associated with some risks and side effects. These can include infusion-related reactions and potentially serious brain swelling or bleeding, known as amyloid-related imaging abnormalities (ARIA). Such adverse events have raised concerns among patients and caregivers, which may be a factor motivating legal claims.
The fact that a proposed class action lawsuit has been filed suggests that some patients or their families believe they have suffered injuries due to lecanemab infusions and are seeking collective legal recourse. Class actions are typically pursued when multiple individuals experience similar harm from a product, allowing them to consolidate their claims for efficiency and stronger impact.
At this stage, the legal landscape is still developing. The filing of a proposed class action indicates that plaintiffs are organizing to challenge the safety or handling of lecanemab infusions, but it is not yet confirmed whether the case will proceed as a formal class action or how broadly it will apply. Patients considering or receiving lecanemab should be aware of potential risks and monitor for any adverse effects, while also staying informed about ongoing legal developments.
In summary, there is a proposed class action lawsuit related to injuries from lecanemab infusions, reflecting emerging legal concerns about the drug’s safety profile. However, no widely recognized or fully established open class action has been publicly confirmed at this time.
